Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project
15-Apr-2005 -
Xantos Biomedicine AG announced a collaboration with NascaCell IP GmbH and PSF biotech AG. The consortium is set to identify and develop new drugs for the inhibition of tumour angiogenesis, a process by which the growth of blood cells from surrounding tissue into a tumor is induced by a protein ...
angiogenesis
education
target validation
+1